Test of EBV CAR-T or TCR-T cells for nasopharyngeal cancer
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This early-phase study tests personalized immune cells (EBV CAR-T or TCR-T) to treat nasopharyngeal cancer that has returned or spread. It aims to help the immune system find and attack the cancer after other treatments have not worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old and can give written consent.
- Your cancer is EBV-positive nasopharyngeal cancer confirmed by a specific lab test (Eber-fish).
- You have at least one measurable tumor area on scans, and you’re expected to live at least 3 months.
- Your prior treatments have not worked (recurrent or metastatic after at least second-line systemic therapy).
- You must be well enough to tolerate treatment (fitness score ECOG 0–2) and prior treatment side effects should be mild (below grade 1).
- You need a way to collect your blood cells (apheresis or venous access).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests a stronger treatment approach for people with locally advanced nasopharyngeal cancer whose EBV “DNA” (a cancer-related virus signal in blood) does not go away after one cycle of chemotherapy. It may help improve outcomes by changing treatment based on how the cancer responds early.
This trial tests a “choose the best treatment” approach for people with nasopharyngeal cancer (NPC) that is linked to EBV (a common virus). By matching treatment to your EBV and cancer features, the study aims to improve outcomes while tracking safety.
This trial is testing a new way to diagnose nasopharyngeal cancer using a special test that looks at a change in the EBV virus DNA. It is for people who may have symptoms of this cancer or have tested positive for EBV, but have not yet been treated.
This trial studies whether tracking levels of Epstein-Barr virus DNA in your blood can help guide treatment for non-metastatic nasopharyngeal cancer. You would get standard radiation and maybe chemotherapy, with extra blood tests to see how the virus levels change.
This trial is for people with high-risk, newly diagnosed stage T3N1M0 nasopharyngeal cancer. It compares whether you need chemotherapy first (before radiation and chemotherapy together) to improve outcomes.
This trial tests a combination of three drugs (gemcitabine, docetaxel, and toripalimab) as a first treatment for a type of nasopharyngeal cancer linked to the Epstein-Barr virus. The goal is to see if this combination helps shrink tumors before other treatments like radiation.
Hear when a new Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.